Literature DB >> 10667507

Lipopolysaccharide binding protein in acute pancreatitis.

P J Erwin1, H Lewis, S Dolan, P S Tobias, R R Schumann, N Lamping, G B Wisdom, B J Rowlands, M I Halliday.   

Abstract

OBJECTIVE: To assess the expression of plasma lipopolysaccharide binding protein (LBP) concentrations and its relationship to markers of the systemic inflammatory response syndrome during acute pancreatitis.
DESIGN: A prospective study.
SETTING: General surgical units of university teaching hospitals in the Belfast area. PATIENTS: The study included 18 patients admitted with established diagnosis of acute pancreatitis on the basis of elevated serum amylase or by contrast radiology. Patients were retrospectively stratified using the Modified Glasgow Criteria into severe (n = 7) and mild (n = 11) disease. INTERVENTIONS AND MEASUREMENTS: Blood samples were obtained at admission (day 1) and for a further 3 days for the measurement of LBP, C-reactive protein (CRP), tumor necrosis factor, and interleukin (IL)-6. Acute Physiology and Chronic Health Evaluation (APACHE) II scores were calculated on day 1 and day 2. MAIN
RESULTS: LBP and CRP concentrations were significantly increased from healthy control values in acute pancreatitis patients at presentation. In the mild group LBP, CRP and IL-6 concentrations remained relatively constant throughout the study period. By comparison, severe acute pancreatitis was associated with significantly higher LBP concentrations and a marked systemic inflammatory response as evidenced by increased CRP, IL-6, and APACHE II scores. The rise in LBP occurred after the observed increase of these markers. Significant correlations were found among CRP and LBP, IL-6 and LBP, and IL-6 and APACHE II scores. There were no fatalities in the mild group, whereas four of the seven patients with severe disease died.
CONCLUSIONS: LBP was significantly raised in patients with severe acute pancreatitis but would seem to be of limited use in predicting disease severity. This acute phase protein may have a role in the progression of systemic complications associated with acute pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10667507     DOI: 10.1097/00003246-200001000-00017

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

1.  Nuclear factor kB activity in patients with acute severe cholangitis.

Authors:  Jian-Ping Gong; Chong-An Liu; Chuan-Xin Wu; Sheng-Wei Li; Yu-Jun Shi; Xu-Hong Li
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

2.  Lipopolysaccharide binding protein is down-regulated during acute liver failure.

Authors:  Grace L Su; Robert J Fontana; Kartik Jinjuvadia; Jill Bayliss; Stewart C Wang
Journal:  Dig Dis Sci       Date:  2012-01-26       Impact factor: 3.199

3.  Clinical value of lipopolysaccharide-binding protein (LBP) determinations in acute pancreatitis.

Authors:  Bettina Rau; Gerald Steinbach; Colin M Krüger; Katja Baumgart; Martin Schilling; Hans G Beger
Journal:  Langenbecks Arch Surg       Date:  2003-07-11       Impact factor: 3.445

4.  Role of NF-kB in multiple organ dysfunction during acute obstructive cholangitis.

Authors:  Bin Tu; Jian-Ping Gong; Hu-Yi Feng; Chuan-Xin Wu; Yu-Jun Shi; Xu-Hong Li; Yong Peng; Chang-An Liu; Sheng-Wei Li
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

5.  In Critically Ill Patients, Serum Procalcitonin Is More Useful in Differentiating between Sepsis and SIRS than CRP, Il-6, or LBP.

Authors:  Iwan A Meynaar; Wouter Droog; Manou Batstra; Rolf Vreede; Paul Herbrink
Journal:  Crit Care Res Pract       Date:  2011-05-15

6.  Development and Validation of a Novel Prognostic Score Based on Thrombotic and Inflammatory Biomarkers for Predicting 28-Day Adverse Outcomes in Patients with Acute Pancreatitis.

Authors:  Tianyong Han; Tao Cheng; Ye Liao; Yarong He; Bofu Liu; Qiang Lai; Pan Pan; Junzhao Liu; Chenxi Lei; Yu Cao
Journal:  J Inflamm Res       Date:  2022-01-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.